Alkermes plc $ALKS Shares Bought by Vontobel Holding Ltd.

Vontobel Holding Ltd. raised its stake in Alkermes plc (NASDAQ:ALKS) by 18.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 47,020 shares of the company’s stock after acquiring an additional 7,347 shares during the quarter. Vontobel Holding Ltd.’s holdings in Alkermes were worth $1,345,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Twin Tree Management LP acquired a new position in Alkermes in the first quarter valued at $29,000. Armstrong Advisory Group Inc. acquired a new position in Alkermes in the second quarter valued at $29,000. Brooklyn Investment Group increased its stake in Alkermes by 1,071.1% in the first quarter. Brooklyn Investment Group now owns 1,054 shares of the company’s stock valued at $35,000 after purchasing an additional 964 shares during the last quarter. Quantbot Technologies LP increased its stake in Alkermes by 54.5% in the first quarter. Quantbot Technologies LP now owns 1,091 shares of the company’s stock valued at $36,000 after purchasing an additional 385 shares during the last quarter. Finally, Fifth Third Bancorp increased its stake in Alkermes by 54.4% in the first quarter. Fifth Third Bancorp now owns 1,479 shares of the company’s stock valued at $49,000 after purchasing an additional 521 shares during the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

Alkermes Trading Down 0.5%

ALKS stock opened at $31.21 on Monday. The stock has a 50-day moving average price of $28.65 and a two-hundred day moving average price of $29.13. Alkermes plc has a 12-month low of $25.17 and a 12-month high of $36.45. The company has a market cap of $5.15 billion, a PE ratio of 15.00, a price-to-earnings-growth ratio of 1.69 and a beta of 0.54.

Alkermes (NASDAQ:ALKS) last issued its earnings results on Tuesday, July 29th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.10. Alkermes had a return on equity of 24.86% and a net margin of 23.15%.The company had revenue of $390.66 million during the quarter, compared to the consensus estimate of $343.20 million. During the same quarter in the prior year, the business earned $1.16 earnings per share. The company’s revenue was down 2.1% compared to the same quarter last year. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS. Equities analysts forecast that Alkermes plc will post 1.31 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on ALKS. Weiss Ratings reiterated a “hold (c)” rating on shares of Alkermes in a research note on Saturday, September 27th. HC Wainwright reiterated a “neutral” rating and issued a $46.00 target price on shares of Alkermes in a research note on Tuesday, September 9th. UBS Group upgraded Alkermes from a “neutral” rating to a “buy” rating and upped their target price for the company from $33.00 to $42.00 in a research note on Tuesday, June 17th. Needham & Company LLC set a $43.00 price target on Alkermes in a research report on Tuesday, September 9th. Finally, JPMorgan Chase & Co. boosted their price target on Alkermes from $34.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.